Top 5 Healthcare Stocks for the Future

Burrage Capital had a 2.7% ownership stake in MEI Pharma Inc (NASDAQ:MEIP) at the end of Q3, the largest position in any of its holdings. Hedge fund ownership of MEIP peaked at the end of June at 20 before sliding back to 16 a quarter later after the company announced in early July that it was discontinuing its Phase 3 trial of Pracinostat after an analysis by the trial’s Independent Data Monitoring Committee found that the study’s survival endpoint was unlikely to be met.

MEIP shares have fallen by 29% since then while the company switches focus to its treatment for B-cell malignancies, zandelisib, which Brookline Capital believes could be commercialized in 2022. MEI Pharma had $183 million in cash in September, which it expects will carry it through 2023.